Johnson & Johnson (STU:JNJ) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:JNJ Johnson & Johnson STU:JNJ
80 GF Score
Price €236.05
GF Value €166.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson  (STU:JNJ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Johnson & Johnson Cyclically Adjusted PS Ratio Related Terms


Johnson & Johnson Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Cyclically Adjusted PS Ratio Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.70 5.77 4.66 4.35 5.32

Johnson & Johnson Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.86 4.66 5.24 6.14 6.39

STU:JNJ vs ABBV, MRK, LLY: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.


STU:JNJ
80GF Score
Johnson & Johnson STU:JNJ
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Johnson & Johnson Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=8.923/333.9520*333.9520
=8.923

Current CPI (Jun. 2026) = 333.9520.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 5.735 241.428 7.933
201612 6.080 241.432 8.410
201703 6.063 243.801 8.305
201706 6.246 244.955 8.515
201709 6.114 246.819 8.272
201712 6.387 246.524 8.652
201803 5.951 249.554 7.964
201806 6.419 251.989 8.507
201809 6.413 252.439 8.484
201812 6.562 251.233 8.723
201903 6.540 254.202 8.592
201906 6.803 256.143 8.870
201909 6.986 256.759 9.086
201912 7.025 256.974 9.129
202003 7.029 258.115 9.094
202006 6.247 257.797 8.092
202009 6.760 260.280 8.673
202012 7.062 260.474 9.054
202103 6.928 264.877 8.735
202106 7.240 271.696 8.899
202109 7.402 274.310 9.011
202112 8.130 278.802 9.738
202203 7.837 287.504 9.103
202206 8.454 296.311 9.528
202209 7.467 296.808 8.401
202212 7.387 296.797 8.312
202303 7.470 301.836 8.265
202306 7.535 305.109 8.247
202309 7.695 307.789 8.349
202312 8.185 306.746 8.911
202403 8.107 312.332 8.668
202406 8.609 314.175 9.151
202409 8.425 315.301 8.923
202412 8.698 315.605 9.204
202503 8.583 319.799 8.963
202506 8.658 322.561 8.964
202509 8.453 324.800 8.691
202512 8.652 324.054 8.916
202603 8.413 330.213 8.508
202606 8.923 333.952 8.923

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Johnson & Johnson (STU:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of €236.05 is trading 41.4% above its estimated GF Value™ of €166.93. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for STU:JNJ:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €166.93 vs. price of €236.05 (41.4% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the STU:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
80GF Score

Get the complete analysis for STU:JNJ

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€236.05
Price
€166.93
GF Value